Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma

NCT00005949 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

NIH

Sponsor class

Conditions

Recurrent Melanoma
Stage IV Melanoma

Interventions

BIOLOGICAL: aldesleukin
BIOLOGICAL: gp100:209-217(210M) peptide vaccine
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)